Aclarion Announces $480,000 Registered Direct Offering to Fund Healthcare Technology Development

Aclarion, Inc. has agreed to sell 3,380,276 shares of common stock at $0.142 per share in a registered direct offering, generating approximately $480,000 in gross proceeds before expenses. The healthcare technology company intends to use these funds to support market development, clinical evidence generation, product development, quality initiatives, and general corporate operations. This capital infusion is crucial for advancing Aclarion's proprietary augmented intelligence algorithms that help physicians identify the source of chronic low back pain, a condition affecting millions worldwide and often leading to invasive procedures when improperly diagnosed.

The offering, expected to close around January 6, 2025, is being conducted under a shelf registration statement previously declared effective by the Securities and Exchange Commission. Dawson James Securities, Inc. serves as the sole placement agent for the transaction. Investors can access detailed offering documents through the SEC's website at https://www.sec.gov, where the final prospectus supplement will be filed and made available free of charge. This transparency ensures regulatory compliance and provides stakeholders with comprehensive information about the investment opportunity.

Aclarion's technology represents a significant advancement in pain management diagnostics. The company's Nociscan platform utilizes Magnetic Resonance Spectroscopy data, proprietary signal processing techniques, and biomarker analysis to distinguish between painful and nonpainful spinal discs. By noninvasively identifying pain sources, the technology enables physicians to develop more targeted treatment strategies, potentially reducing unnecessary surgeries and improving patient outcomes. The funding from this offering will accelerate clinical validation and market expansion efforts, bringing this innovative solution to more healthcare providers and patients suffering from chronic back pain.

The importance of this financing extends beyond corporate growth to broader healthcare implications. Chronic low back pain represents a substantial burden on healthcare systems globally, often resulting in extensive diagnostic procedures, conservative treatments, and surgical interventions. Aclarion's approach could streamline diagnosis, reduce healthcare costs, and improve quality of life for patients. The company's use of augmented intelligence algorithms demonstrates how technology is transforming traditional medical diagnostics, offering more precise and objective assessment tools than conventional methods alone.